Chester County News and Community Website
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) reported recently updated clinical data for its PBFT02 therapy in frontotemporal dementia and said it has initiated a strategic review process following …
Passage Bio Reports Trial Data, Reviews Strategic Options Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) reported fourth-quarter and full-year 2025 financial results while providing updates on its clinical program studying PBFT02, a gene therapy candidate for genetic …
Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) announced that its management team will participate in two upcoming investor conferences in February and March, where executives will deliver presentations and …
Passage Bio Management to Present at Two Healthcare Conferences Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) reported third-quarter financial results and outlined steady progress across its upliFT-D gene therapy program, positioning the company for critical regulatory and clinical …
Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that its president and chief executive officer, Will Chou, M.D., will participate in a panel discussion at the Chardan 9th Annual …
Passage Bio CEO to Speak at Chardan Genetic Medicines Conference Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that its management team will participate in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8–10, 2025, in …
Passage Bio to Present at H.C. Wainwright Global Investment Conference Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) announced second-quarter 2025 results and reported key advancements in its upliFT-D clinical trial, including completion of dosing in the second cohort of …
Passage Bio Reports Strong Progress in FTD-GRN Gene Therapy Trial, Extends Cash Runway to 2027 Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that its Board of Directors has approved a 1-for-20 reverse stock split, set to take effect at 12:01 a.m. Eastern time …
Passage Bio Approves 1-for-20 Reverse Stock Split to Maintain Nasdaq Compliance Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced encouraging updates from the ongoing Phase 1/2 upliFT-D clinical trial for PBFT02, a one-time gene therapy for frontotemporal dementia (FTD) …
Passage Bio Reports Progress in Gene Therapy for Frontotemporal Dementia Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared its financial results for the first quarter of 2025, along with updates on its ongoing clinical programs and operational advancements. …
Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development Read More